PolyPid Dividends and Buybacks

Dividend criteria checks 0/6

PolyPid does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-55.8%

Buyback Yield

Total Shareholder Yield-55.8%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

PolyPid set to cut 20% jobs

Oct 20

PolyPid's surgical site infections treatment eligible for marketing nod submission in EU

Sep 28

PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections

Sep 02

PolyPid GAAP EPS of -$1.23 misses by $0.60

Aug 10

PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe

Aug 03

PolyPid: Strong Pipeline, Close Catalysts

Apr 19

Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?

Mar 18
Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?

Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation

Nov 08
Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation

We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth

Jul 15
We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

Mar 09
Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

PolyPid's oncoplex cancer program shows encouraging action in animal study

Dec 22

PolyPid launches second late-stage trial with D-PLEX100 in surgical infections

Dec 16

PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections

Nov 24

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if PYPD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PYPD's dividend payments have been increasing.


Dividend Yield vs Market

PolyPid Dividend Yield vs Market
How does PYPD dividend yield compare to the market?
SegmentDividend Yield
Company (PYPD)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.5%
Industry Average (Pharmaceuticals)2.5%
Analyst forecast (PYPD) (up to 3 years)n/a

Notable Dividend: Unable to evaluate PYPD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PYPD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate PYPD's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PYPD has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 11:52
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PolyPid Ltd. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Balaji PrasadBarclays
Gary NachmanBMO Capital Markets Equity Research
Brandon FolkesCantor Fitzgerald & Co.